McCarthy Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

McCarthy Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-375	Closed	-$1K	–	332
2022 Q1	$1K	Hold	375	–	–	﹤0.01%	330
2021 Q4	$2K	Hold	375	–	–	﹤0.01%	306
2021 Q3	$3K	Hold	375	–	–	﹤0.01%	262
2021 Q2	$4K	Hold	375	–	–	﹤0.01%	277
2021 Q1	$3K	Hold	375	–	–	﹤0.01%	274
2020 Q4	$3K	Buy	+375	New	+$3.01K	﹤0.01%	251

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

McCarthy Asset Management's SRNE Position: Q2 2022 in Review

McCarthy Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2022, closing a stake of 375 shares — an estimated $1K sold.

McCarthy Asset Management first reported a position in SRNE in Q4 2020 and held it in 6 quarters. The position peaked at $4K in Q2 2021. 229 funds tracked by Wall St. Rank hold SRNE as of Q2 2022.

McCarthy Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 375 Sorrento Therapeutics, Inc. shares in Q2 2022, an estimated $1K.
McCarthy Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 6 quarters.
McCarthy Asset Management's Sorrento Therapeutics, Inc. position peaked at $4K in Q2 2021.
229 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.